Baseline contractile function and coronary flow in hearts isolated from placebo-treated or morphine-treated mice
Data were acquired after 30-min aerobic perfusion (and at a fixed pacing rate of 420 beats per minute). Data are means ± S.E.M.
| Group | LVEDP | LVDP | Heart Rate | Coronary Flow |
|---|---|---|---|---|
| mm Hg | beats/min | ml/min/g | ||
| SLP | ||||
| 5-Day placebo (n = 13) | 5 ± 1 | 153 ± 9 | 420 ± 3 | 2.7 ± 0.2 |
| 5-Day SLP (n = 11) | 6 ± 2 | 150 ± 3 | 422 ± 1 | 2.8 ± 0.4 |
| Effect of stimulus withdrawal (5-day SLP) | ||||
| 3-Day withdrawal (n = 8) | 5 ± 1 | 148 ± 4 | 427 ± 2 | 2.7 ± 0.2 |
| 5-Day withdrawal (n = 6) | 4 ± 2 | 153 ± 3 | 424 ± 1 | 2.7 ± 0.2 |
| 7-Day withdrawal (n = 8) | 3 ± 2 | 143 ± 10 | 430 ± 32 | 3.2 ± 0.2 |
| Inhibitors in the induction phase (5-day SLP) | ||||
| Naloxone (n = 6) | 5 ± 1 | 146 ± 4 | 425 ± 5 | 2.7 ± 0.1 |
| SLP + naloxone (n = 8) | 8 ± 1 | 152 ± 9 | 445 ± 19 | 3.6 ± 0.2 |
| PKI (n = 7) | 3 ± 1 | 148 ± 3 | 424 ± 5 | 2.5 ± 0.2 |
| SLP + PKI (n = 7) | 7 ± 1 | 142 ± 9 | 406 ± 11 | 2.8 ± 0.1 |
| Wortmannin (n = 6) | 3 ± 1 | 153 ± 6 | 419 ± 1 | 3.1 ± 0.1 |
| SLP + wortmannin (n = 10) | 3 ± 1 | 128 ± 5 | 435 ± 6 | 2.9 ± 0.5 |
| Opioid receptor specificity (5-day SLP) | ||||
| SLP + nor-BNI (n = 8) | 6 ± 1 | 149 ± 4 | 435 ± 39 | 2.5 ± 0.2 |
| SLP + BNTX (n = 6) | 4 ± 1 | 154 ± 3 | 416 ± 2 | 2.6 ± 0.1 |
| SLP (BW373U86) (n = 10) | 5 ± 1 | 137 ± 6 | 428 ± 1 | 2.5 ± 0.1 |
| SLP (U50,488) (n = 9) | 3 ± 2 | 148 ± 5 | 422 ± 5 | 3.2 ± 0.2 |
| Additivity of protection | ||||
| A1AR TG (n = 7) | 4 ± 1 | 138 ± 8 | 418 ± 2 | 3.2 ± 0.2 |
| SLP + A1AR TG (n = 8) | 5 ± 1 | 127 ± 8 | 424 ± 9 | 3.6 ± 0.3 |
LVEDP, left ventricular end-diastolic pressure.